Search Within

Gregory J Riely

Formats
  1. Journal Article (295)
  2. Meeting Abstract (265)
  3. Book Section (16)
  4. Guidelines (16)
  5. Conference Paper (4)
  6. Review (4)
  7. Editorial (3)
  8. Correspondence (2)
  9. Book Whole (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (607)
  2. Solid Tumor Oncology Division (607)
  3. Thoracic Oncology (607)
  4. Department of Pathology and Laboratory Medicine (263)
  5. GSK Faculty (248)
  6. Human Oncology and Pathogenesis Program (223)

More Groups

People
  1. Mark Kris (222)
  2. Marc Ladanyi (188)
  3. Helena Yu (108)
  4. Maria Arcila (85)
  5. Vincent Miller (79)
  6. Charles Rudin (76)

More People

Years
  1. 2025 (11)
  2. 2024 (25)
  3. 2023 (45)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (29)

More Years

Publications
  1. Journal of Clinical Oncology (157)
  2. Journal of Thoracic Oncology (113)
  3. Clinical Cancer Research (46)
  4. Annals of Oncology (32)
  5. Journal of the National Comprehensive Cancer Network (27)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (175)
  2. Elsevier Inc. (138)
  3. American Association for Cancer Research (77)
  4. Oxford University Press (39)
  5. Harborside Press (27)
  6. Elsevier Science, Inc. (23)

More Publishers

Results (607)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RET-rearranged lung cancers: Immunophenotype and response to immunotherapy
    Meeting Abstract

    Sabari, J. K.; Offin, M. D.; Wu, S. L.; Ni, A.; Halpenny, D.; Montecalvo, J.; Liu, D.; Pak, T. K.; Arbour, K. C.; Lai, W. C. V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers
    Meeting Abstract

    Offin, M. D.; Rizvi, H.; Tenet, M.; Ni, A.; Sanchez Vega, F.; Kris, M. G.; Rudin, C. M.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies
    Meeting Abstract

    Lu, M.; Sadetsky, N.; Lambert, P.; Whipple, S.; Taylor, M. D.; Riehl, T.; Riely, G. J.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers
    Meeting Abstract

    Kris, M. G.; Offin, M. D.; Feldman, D. L.; Ni, A.; Lai, W. C. V.; Arbour, K. C.; Daras, M.; Pentsova, E.; DeAngelis, L. M.; Beal, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC)
    Meeting Abstract

    Kim, D. W.; Gadgeel, S. M.; Gettinger, S. N.; Riely, G. J.; Oxnard, G. R.; Mekhail, T.; Schmid, P.; Dowlati, A.; Heist, R. S.; Wozniak, A. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Doebele, R. C.; Riely, G. J.; Spira, A. I.; Horn, L.; Piotrowska, Z.; Costa, D. B.; Neal, J. W.; Zhang, S.; Reichmann, W.; Kerstein, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Lorlatinib in patients (Pts) with previously treated ALK(+) advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety
    Meeting Abstract

    Besse, B.; Solomon, B. J.; Felip, E.; Bauer, T. M.; Ou, S. H. I.; Soo, R. A.; Camidge, D. R.; Chiari, R.; Gadgeel, S. M.; Riely, G. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC
    Meeting Abstract

    Arbour, K. C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Bernal, G. M.; Chaft, J. E.; Ferrara, R.; Lai, W. C. V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Somwar, R.; Rekhtman, N.; Benayed, R.; Chang, J. C.; Plodkowski, A.; Lui, A. J. W.; Eng, J.; Rosenblum, M.; Li, B. T.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
    Meeting Abstract

    Shaw, A. T.; Martini, J. F.; Besse, B.; Bauer, T. M.; Lin, C. C.; Soo, R. A.; Riely, G. J.; Ou, S. H. I.; Clancy, J. S.; Li, S.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save